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Bezlotoxumab Is Associated With a Reduction in 
Cumulative Inpatient-Days: Analysis of the Hospitalization 
Data From the MODIFY I and II Clinical Trials
Anirban Basu,1 Vimalanand S. Prabhu,2 Mary Beth Dorr,2 Yoav Golan,3 Erik R. Dubberke,4 Oliver A. Cornely,5 Sebastian M. Heimann,6  
Alison Pedley,2 Ruifeng Xu,2 Mary E. Hanson,2 and Stephen Marcella2
1The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, Washington; 2Merck & Co., Inc., Kenilworth, New Jersey; 3New England 
Medical Center, Tufts University, Boston, Massachusetts; 4Department of Medicine, Washington University, St. Louis, Missouri; 5Cologne Excellence Cluster on Cellular Stress Responses in 
Aging-Associated Diseases (CECAD), Department I of Internal Medicine, ECMM Excellence Center of Medical Mycology, Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, 
Germany; 6Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
Background. Patients with recurrent Clostridium difficile infection (rCDI) are more likely to have a hospital readmission and 
spend increased time in inpatient settings compared with patients with primary CDI. MODIFY I and II demonstrated that bezlotox-
umab significantly reduced rCDI vs placebo. A post hoc within-trial analysis assessed whether bezlotoxumab was associated with a 
reduction in cumulative inpatient-days.
Methods. Data were pooled from the MODIFY trials to estimate the cumulative hospitalized days summed over the 84-day 
follow-up period. We adjusted inpatient use data from pooled MODIFY I and II for survival and censoring to estimate 84-day cumu-
lative inpatient-days, overall and for subgroups. Treatment effects were obtained using recycled predictions based on trial protocol 
and rCDI risk, and 95% confidence intervals were obtained using 1000 bootstrap replicates.
Results. Mean cumulative inpatient-days were greater in the placebo arm (14.1 days) vs the bezlotoxumab arm (12.1 days) in 
the overall population. The mean difference between treatment groups was 2.1 days (95% confidence interval, –0.4 to –3.7). This 
was consistent in participants with risk factors for rCDI: age ≥65 years, compromised immunity, severe CDI, prior CDI, and ribo-
type 027/078/244 infection. As the number of risk factors increased, bezlotoxumab resulted in greater reductions in the number 
of inpatient-days compared with placebo (difference: –1.2 days, –2.3 days, –2.5 days, and –3.0 days for 0, 1, 2, and ≥3 risk factors, 
respectively).
Conclusions. Bezlotoxumab was associated with a reduction in cumulative inpatient-days, suggesting that treatment with bez-
lotoxumab may substantially reduce rCDI-associated health care resource use.
Trial registrations. MODIFY I (MK-3415A-001, NCT01241552) and II (MK-3415A-002, NCT01513239)
Keywords. CDI burden of disease; Clostridium difficile infection; recurrence; rehospitalization. 
Approximately 25% of patients experience recurrent 
Clostridium difficile infection (rCDI) after completing initial 
therapy with metronidazole or vancomycin [1, 2]. The risk of a 
second recurrence increases to approximately 40% [3] with sig-
nificantly increasing costs for inpatients with rCDI compared 
with primary CDI [4]. Factors associated with an increase in 
rCDI include age ≥65 years [5], inadequate immune response 
[6], severe CDI [7, 8], prior CDI episode(s) [3], and infection 
with the B1/NAP1/027 strain [9–12].
Overall, patients with rCDI experience significantly higher 
rates of hospital readmission vs patients without rCDI (85% 
vs 41%) [13] and have longer hospital stays (19 days vs 8 days; 
P < .001) [13]; more than 40% of index hospitalizations associ-
ated with CDI result in discharge to long-term care, followed 
by readmission to the hospital within 90 days (all-cause read-
missions) [14]. Recurrent episodes of CDI are associated with 
excessive costs, and these are attributable to significantly longer 
hospital stays, including more days in the intensive care unit in 
tertiary care settings, compared with primary episodes of CDI 
[4, 15].
The human monoclonal antibody bezlotoxumab is a novel 
antitoxin agent that, when given as a single intravenous dose dur-
ing standard of care antibiotic therapy, reduced rCDI compared 
with antibiotic therapy alone (placebo group) over a 12-week 
period in 2 independent, phase III, global trials (adjusted dif-
ference between groups in rCDI was –10.1% in MODIFY I and 
–9.9% in MODIFY II; both P <  .001) [16]. Furthermore, in a 
post hoc analysis, the reduction in rCDI was greater in partici-
pants at high risk for rCDI (adjusted difference between groups 
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in rCDI was –15.9% (95% confidence interval [CI], –21.6 
to –10.2) in participants with ≥1 risk factor for rCDI) [17]. 
Bezlotoxumab neutralizes C. difficile toxin B. Neutralization of 
toxin B prevents new symptoms of CDI during the period when 
there is a high risk of rCDI, thereby preventing clinical relapse.
Bezlotoxumab’s demonstrated efficacy in reducing rCDI over 
a 12-week period suggests that health care resource utilization 
and associated costs may also be reduced in patients receiving 
bezlotoxumab. This post hoc analysis was conducted to assess 
whether bezlotoxumab reduced the number of days partici-
pants spent in the hospital (cumulative inpatient-days) over a 
12-week period compared with placebo.
METHODS
MODIFY I (NCT01241552) and II (NCT01513239) were ran-
domized, double-blind, placebo-controlled, multicenter, phase 
III trials that were conducted from November 2011 through 
May 2015 at 322 sites in 30 countries. The protocols and all 
amendments were approved by the institutional review board 
or independent ethics committee at each study center. Each 
study was conducted in accordance with Good Clinical Practice 
Guidelines and the Declaration of Helsinki. Written informed 
consent was obtained before study procedures were performed.
Participants
Adults with primary or rCDI receiving oral standard of care anti-
biotics (metronidazole, vancomycin, or fidaxomicin, chosen by 
the treating physician) for 10–14 days were included in the trial. 
CDI was defined as diarrhea (≥3 unformed bowel movements 
in 24 hours) associated with a positive stool test for toxigenic 
C. difficile or its toxins. To monitor for new episodes of diarrhea, 
participants recorded daily loose stool counts in a diary through 
12 weeks. Participants included in this analysis received either a 
single dose of bezlotoxumab 10 mg/kg or placebo (0.9% saline) 
during antibiotic treatment. Randomization was stratified by oral 
antibiotic treatment for CDI (metronidazole, vancomycin, or fid-
axomicin) and hospitalization status (inpatient or outpatient).
Population, End Points, and Statistical Methods
The analysis population was the modified intent-to-treat 
(mITT) population (defined as all randomly assigned partici-
pants who received study infusion, had a positive stool test for 
toxigenic C. difficile or its toxins, and began standard of care 
antibiotic therapy before or within 1  day after receiving the 
study infusion) in the pooled data set from MODIFY I  and 
MODIFY II. Subgroups were characterized by known risk fac-
tors for CDI recurrence that had been prespecified in the pro-
tocols: ≥65  years of age, immunocompromised, severe CDI, 
hypervirulent strain (ribotypes 027, 078, or 244), and/or ≥1 epi-
sode of CDI in previous 6 months. Additional subgroups were 
defined based on the total number of prespecified risk factors: 
no risk factors, at least 1 risk factor, only 1 risk factor, only 2 
risk factors, and ≥3 risk factors. The primary end point for this 
post hoc analysis was cumulative inpatient-days in any hospital 
setting during the 84 days following infusion.
We first modeled the probability of surviving each follow-up 
day, after adjusting for censoring using a standard accelerated 
failure time model. Then, using the longitudinal data set of up 
to 84 observations per person, we estimated the probability of 
spending a day in the hospital using a logistic model. The inde-
pendent variables for this model included sex, race, age, inpa-
tient status, NAP 1 strain, Charlson Severity Score, history of 
CDI, being immunocompromised, and region (US vs ex-US). 
Lin’s (2000) method was applied, where the day-specific prob-
ability of spending a day in the hospital among those noncen-
sored was multiplied by the estimated day-specific probability 
of survival and then summed over all 84 days to obtain the esti-
mate of cumulative inpatient-days, adjusted for censoring [18]. 
Censoring occurred, as cost data were not available for patients 
who discontinued from the trial. Lin’s method was adopted to 
account for censoring by appropriately weighting the uncen-
sored costs with inverse probability of inclusion (survival 
probability). Lin’s method is an improvement over traditional 
methods such as analyzing censored cost data by excluding sub-
jects, as these methods do not utilize complete information by 
ignoring censored subjects and may result in bias. Treatment 
effects were obtained using recycled predictions by turning on 
and off the treatment indicator for all participants in our over-
all sample and for subgroups identified based on trial protocol 
and risk of rCDI. P values and 95% confidence intervals were 
obtained using 1000 clustered bootstrap replicates. Statistical 
analyses were conducted using Stata, version 11.
RESULTS
Study Population
There were 1554 participants (bezlotoxumab group: 781; pla-
cebo group: 773) included in the mITT population across both 
studies. Demographic and clinical characteristics were balanced 
between the study groups (Table 1) and have been previously 
reported [16]. The median age (range) was 66 (18–100) years, 
86% were white, and 56% were women.
Treatment with bezlotoxumab was associated with a reduc-
tion in cumulative inpatient-days compared with placebo 
(Figure 1) during 84 days of follow-up. In the overall popula-
tion, participants treated with bezlotoxumab spent an average of 
2.1 fewer days (95% CI, –0.4 to –3.7) in the hospital compared 
with participants who received placebo. Similarly, in all sub-
groups assessed, including those with no risk factors and those 
with factors associated with rCDI, bezlotoxumab treatment was 
associated with a reduction in cumulative inpatient-days com-
pared with those receiving placebo during the 84-day follow-up 
period. The greatest reduction in inpatient-days was observed 
in participants with severe CDI at study entry (–3.5  days) 
(Figure  1). As the number of risk factors for rCDI increased, 
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with bezlotoxumab vs placebo (difference: –1.2 days in partici-
pants with no risk factors, –2.3 days in those with 1 risk factor, 
–2.5 days in those with 2 risk factors, and –3.0 days in those 
with ≥3 risk factors) (Figure 1).
DISCUSSION
We used pooled data from 2 placebo-controlled, multicenter 
clinical trials to assess the impact of bezlotoxumab treatment 
on cumulative inpatient-days from any cause over 84  days of 
follow-up. Our post hoc analysis demonstrated that bezlotox-
umab treatment was associated with reduced cumulative inpa-
tient stay of 2.1 days in the overall trial population, with even 
greater reductions observed in participants with 1 or more risk 
factors associated with recurrence of CDI. The inpatient sub-
group, presumably a sicker subgroup, is also noted to have a 
larger reduction in cumulative inpatient-days. As the number of 
risk factors increased, participants treated with bezlotoxumab 
experienced incrementally greater reductions in the cumulative 
inpatient-days compared with placebo.
A 2014 model-based estimate of the economic burden of 
CDI in the United States was substantial at $5.4 billion, mainly 
attributable to hospitalization [19]. A  US MarketScan data-
base study with coverage of more than 45 million members 
estimated the 6-month health care costs attributable to rCDI 
at $10 580 (95% CI, $8849 to $12 446), with cumulative hos-
pitalized days attributable to rCDI of 1.95 (95% CI, 1.48 to 
2.43) [20], comparable to the study by Dubberke et al. (2014) in 
which the estimated attributable cost of rCDI was $11 631 (95% 
CI, $8937 to $14 588) [4]. With the incidence of CDI-associated 
hospital readmissions rising [13], it is important to find inno-
vative treatment options to reduce rCDI and rCDI-associated 
hospital admissions. The results of the current analysis are con-
sistent with a related post hoc analysis of the MODIFY trials in 
the subgroup of participants who were hospitalized at the time 
of randomization, demonstrating that bezlotoxumab-treated 
inpatients experienced fewer CDI-associated readmissions dur-
ing the 30 days after discharge compared with placebo-treated 
inpatients [21].
 The MODIFY trials, which included a prespecified sub-
group analysis of participants with risk factors associated with 
an increase in rCDI or CDI-related adverse outcomes, afforded 
an opportunity to examine differences in all-cause cumulative 
inpatient-days in an unbiased manner. In the post hoc ana-
lysis at hand, we observed that as the number of risk factors 
increased, the number of cumulative inpatient-days in the pla-
cebo arm also increased, suggesting that the presence of multi-
ple risk factors is associated with an increase in number of days 
spent in an inpatient facility. This is consistent with another 
post hoc analysis of the MODIFY trials that demonstrated 
that the proportion of participants experiencing rCDI in the 
placebo arm increased as the number of risk factors increased 
[17]. Regardless of the number of risk factors, treatment with 
bezlotoxumab was associated with a reduction in cumulative 
inpatient-days during the 84-day follow-up period compared 
with placebo. Taken together, bezlotoxumab treatment is con-
sistent with an overall reduction in recurrence, readmissions, 
and cumulative inpatient-days, suggesting that its use may be an 
effective treatment for reducing the overall health care resource 
use associated with CDI.
 A  cost-effectiveness model showed that bezlotoxumab is 
cost-effective in the prevention of recurrent CDI compared 
with placebo among participants receiving standard of care 
antibiotics for treatment of CDI [22]. With the average cost 
for 1 inpatient-day in the United States estimated at $2013 in 
2015 [23], and an estimated reduction in hospital-days of 2.0 
to 3.0  days, depending upon the number of risk factors, the 
evidence suggests that treatment with bezlotoxumab may sub-
stantially reduce direct treatment costs associated with rCDI. 
A within-trial health-economic evaluation is needed to further 






Inpatient 530 (67.9) 520 (67.3)
Female sex 442 (56.6) 449 (58.1)
Age ≥65 y 390 (49.9) 405 (52.4)
SOC antibiotic
 Metronidazole 365 (46.7) 353 (45.7)
 Vancomycin 370 (47.4) 372 (48.1)
 Fidaxomicin 30 (3.8) 30 (3.9)
≥1 episode of CDI in previous 6 mo 216 (27.7) 219 (28.3)
≥2 previous CDI episodes ever 100 (12.8) 126 (16.3)
Severe CDIa 122 (15.6) 125 (16.2)
Immunocompromisedb 178 (22.8) 153 (19.8)
Other antibiotic use during SOC therapyc 292 (37.4) 317 (41.0)
Other antibiotic use after SOC therapyc 273 (35.0) 275 (35.6)
Renal impairmentd 123 (15.7) 110 (14.2)
Hepatic impairmente 49 (6.3) 44 (5.7)
PCR ribotype
 Participants with positive culture 490 (62.7) 486 (62.9)
 027, 078, or 244 strainf 102 (20.8) 115 (23.7)
 027 strainf 89 (18.2) 100 (20.6)
Abbreviations: CDI, Clostridium difficile infection; PCR, polymerase chain reaction; SOC, 
standard of care. 
aSevere infection was defined as a Zar score of 2 or higher. The Zar score ranges from 1 
to 8 and is based on the following factors: age greater than 60 years (1 point), body tem-
perature higher than 38.3°C (100°F) (1 point), albumin level lower than 2.5 g per deciliter 
(1 point), peripheral white cell count higher than 15 000 per cubic millimeter within 48 
hours (1 point), endoscopic evidence of pseudomembranous colitis (2 points), and treat-
ment in an intensive care unit (2 points).
bThe determination of whether a participant was immunocompromised was made on the 
basis of medical history or use of immunosuppressive therapy.
cIncluded are systemic antibiotics other than the standard of care antibiotic that was 
given to treat C. difficile infection.
dRenal impairment was defined as a serum creatinine level of 1.5 mg per deciliter 
(133 μmol per liter) or higher.
eHepatic impairment was defined as having 2 or more of the following: an albumin level 
of 3.1 g per deciliter or lower, an alanine aminotransferase level at least 2 times the upper 
limit of the normal range, a total bilirubin level at least 1.3 times the upper limit of the nor-
mal range, or mild, moderate, or severe liver disease (as reported on the Charlson Index).
fThe denominators used to calculate percentages are the numbers of participants who 
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assess the value of bezlotoxumab, as bezlotoxumab could poten-
tially be cost-saving among patients with ≥1 risk factor. Further, 
this work is consistent with the labeled claim for bezlotoxumab 
and data demonstrating that bezlotoxumab has a higher impact 
where it matters—among patients who are at risk for rCDI [17].
There are some limitations of this post hoc analysis. First, it was 
not powered for hypothesis testing. In addition, we did not assess 
CDI-associated hospital-days; rather we assessed days spent in the 
hospital for any reason. Therefore, we may be overestimating the 
specific CDI burden, although the amount of overestimation should 
be equivalent for both the bezlotoxumab and placebo groups. One 
population-based, retrospective cohort study among adult inpa-
tients in 29 hospitals found that the risk of readmission for CDI 
was higher in the first 12 weeks after discharge; after 12 weeks, the 
risk of readmission dropped to a stable, low level, suggesting that 
we captured the majority of CDI-associated readmissions during 
the 84-day follow-up period [24]. Of note, the MODIFY trials may 
have enrolled a healthier population compared with real-world 
patients with CDI (despite including a broad population with few 
exclusion criteria), potentially reducing the estimated number of 
non-CDI-related hospital-days in this analysis. Another limitation 
was that we only counted acute care hospitalization–days and did 
not count days in a long-term care facility or rehabilitation center. 
As with any clinical trial, there was early loss to follow-up of some 
patients, which could lead to underestimation of average hospi-
tal-days. Our methods directly addressed this censoring using a 
missing-at-random assumption.
In conclusion, the analysis presented here suggests that bez-
lotoxumab treatment may result in reduced health care resource 
utilization, especially among patients at high risk for CDI 
recurrence.
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Figure 1. Estimated mean cumulative inpatient-days summed over 84 days in the modified intent-to-treat population. aInpatients at the time of study randomization. bHis-
tory of Clostridium difficile infection recurrence within the previous 6 months. cDefined on the basis of a subject’s medical history or use of immunosuppressive therapy. dZar 
score ≥2 based on the following: (1) age >60 years (1 point); (2) body temperature >38.3°C (>100°F; 1 point); (3) albumin level <2.5 mg/dL (1 point); (4) peripheral white blood 
cell count >15 000 cells/mm
3 within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2 points); and (6) treatment in an intensive care unit (2 points). 
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